Emmaus Life Sciences appoints Willis Lee as CEO, eliminates interim Co-President role

Emmaus Life Sciences, Inc.

Willis Lee appointed CEO effective July 15, 2024; previously interim Co-President and COO.
Lee continues as Chairman of the Board (since Oct 2023); compensation unchanged.
George Sekulich, former interim Co-President, continues as Chief Commercial and Information Officer.
Move eliminates the interim Co-President structure.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Willis Lee

Chief Executive Officer

EMMA · Emmaus Life Sciences, Inc.

Effective: 2024-07-15
Filed: July 17, 2024, 7:59 PM ET

On July 15, 2024, the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed Willis Lee as our Chief Executive Officer and eliminated the former offices of interim Co-President.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Willis Lee was appointed as Chief Executive Officer at Emmaus Life Sciences, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On July 15, 2024, the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed Willis Lee as our Chief Executive Officer and eliminated the former offices of interim Co-President.

View on SEC.gov

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-062226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.